{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T17:30:06Z","timestamp":1787333406315,"version":"build-2736575974"},"reference-count":49,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1,30]]},"abstract":"<jats:sec>\n                    <jats:title>Backgrounds:<\/jats:title>\n                    <jats:p>Sacubitril\/valsartan (angiotensin receptor neprilysin inhibitor [ARNi]) effectively treats heart failure with reduced ejection fraction. Its impact on advanced chronic kidney disease (CKD) or end-stage renal disease (ESRD) remains unclear due to their exclusion from major trials. We aimed to evaluate ARNi\u2019s effectiveness and safety in these populations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We systematically searched PubMed, Cochrane, Embase, and ClinicalTrials.gov for observational studies of ARNi use in adults with advanced CKD or ESRD requiring maintenance dialysis. Primary outcomes were all-cause mortality and heart failure hospitalization (HHF), with secondary outcomes focusing on left ventricular ejection fraction (LVEF), blood pressure, and biomarkers. A random-effects model was used to derive pooled estimates, and study quality was assessed using the Newcastle-Ottawa scale.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Ten observational studies included 4329 patients with advanced CKD or ESRD. The pooled odds ratio (OR) for mortality plus HHF was 0.54 (95% confidence interval [CI]: 0.25\u20131.18,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.12). Subgroup analysis showed ORs of 0.67 (95% CI: 0.17\u20132.70) for ESRD and 0.64 (95% CI: 0.25\u20131.66) for CKD. The pooled OR for mortality alone was 0.86 (95% CI: 0.50\u20131.46,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.57). In ESRD, ARNi was linked to significant LVEF improvement (+4.20%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&lt;\u2005.001) and reduced systolic blood pressure (\u22127.13\u2009mm Hg,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.008), without increased risk of hyperkalemia or hypotension.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>In advanced CKD and ESRD with heart failure with reduced ejection fraction, ARNi did not significantly reduce mortality or HHF but showed potential benefit in LVEF improvement. Larger randomized trials are required to confirm its efficacy and safety in this high-risk population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000046866","type":"journal-article","created":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T17:00:28Z","timestamp":1769965228000},"page":"e46866","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["The effectiveness and safety of sacubitril\/valsartan in real-world dialysis patients with heart failure reduced ejection fraction"],"prefix":"10.1097","volume":"105","author":[{"given":"Kuan-Chieh","family":"Tu","sequence":"first","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Chi Mei Medical Center, Tainan, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Chieh","family":"Weng","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Chi Mei Medical Center, Tainan, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Te","family":"Liao","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Chi Mei Medical Center, Tainan, Taiwan"},{"name":"School of Medicine, College of Medicine, National Sun Yat-sen University, Kaohsiung City, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3290-1909","authenticated-orcid":false,"given":"Jheng-Yan","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Nutrition, Chi Mei Medical Center, Tainan, Taiwan"},{"name":"Department of Public Health, College of Medicine, National Cheng Kung University, Tainan City, Taiwan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260519","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1093\/cvr\/cvac013","article-title":"Global burden of heart failure: a comprehensive and updated review of epidemiology.","volume":"118","author":"Savarese","year":"2023","journal-title":"Cardiovasc Res"},{"key":"R2-20260519","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC.","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur Heart J"},{"key":"R3-20260519","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure.","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"R4-20260519","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1042\/CS20130294","article-title":"The central renin-angiotensin system and sympathetic nerve activity in chronic heart failure.","volume":"126","author":"Zucker","year":"2014","journal-title":"Clin Sci (Lond)"},{"key":"R5-20260519","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/nrcardio.2016.163","article-title":"Neurohormonal activation in heart failure with reduced ejection fraction.","volume":"14","author":"Hartupee","year":"2017","journal-title":"Nat Rev Cardiol"},{"key":"R6-20260519","first-page":"1017","article-title":"Roles of natriuretic peptides and the significance of neprilysin in cardiovascular diseases.","volume":"11","author":"Nakagawa","year":"2022","journal-title":"Biology (Basel)"},{"key":"R7-20260519","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1159\/000519905","article-title":"Are post hoc analyses on subgroups sufficient to support new treatment algorithms of heart failure? The case of SGLT2 inhibitors associated with sacubitril\/valsartan.","volume":"147","author":"Volpe","year":"2022","journal-title":"Cardiology"},{"key":"R8-20260519","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure.","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"R9-20260519","doi-asserted-by":"crossref","first-page":"24","DOI":"10.14740\/cr813","article-title":"Anti-hypertensive effect of sacubitril\/valsartan: a meta-analysis of randomized controlled trials.","volume":"10","author":"De Vecchis","year":"2019","journal-title":"Cardiol Res"},{"key":"R10-20260519","doi-asserted-by":"crossref","first-page":"e322","DOI":"10.1097\/MJT.0000000000000925","article-title":"Efficacy of sacubitril\/valsartan in hypertension.","volume":"29","author":"Malik","year":"2022","journal-title":"Am J Ther"},{"key":"R11-20260519","doi-asserted-by":"crossref","first-page":"890481","DOI":"10.3389\/fcvm.2022.890481","article-title":"Effect of sacubitril\/valsartan on reducing the risk of arrhythmia: a systematic review and meta-analysis of randomized controlled trials.","volume":"9","author":"Wang","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"R12-20260519","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1161\/CIRCULATIONAHA.122.060841","article-title":"The effects of angiotensin receptor-neprilysin inhibition on major coronary events in patients with acute myocardial infarction: insights from the PARADISE-MI trial.","volume":"146","author":"Mehran","year":"2022","journal-title":"Circulation"},{"key":"R13-20260519","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s12933-022-01545-1","article-title":"Effects of sacubitril\/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trials.","volume":"21","author":"Wijkman","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"R14-20260519","doi-asserted-by":"crossref","first-page":"108056","DOI":"10.1016\/j.jdiacomp.2021.108056","article-title":"Potential effects and application prospect of angiotensin receptor-neprilysin inhibitor in diabetic kidney disease.","volume":"36","author":"Zhang","year":"2022","journal-title":"J Diabetes Complications"},{"key":"R15-20260519","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.jjcc.2019.03.010","article-title":"Sacubitril\/valsartan in heart failure with reduced ejection fraction patients: real world experience on advanced chronic kidney disease, hypotension, and dose escalation.","volume":"74","author":"Chang","year":"2019","journal-title":"J Cardiol"},{"key":"R16-20260519","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.nefroe.2019.12.002","article-title":"Sacubitril\/valsartan in chronic kidney disease, the nephrologist point of view.","volume":"39","author":"Quiroga","year":"2019","journal-title":"Nefrologia (Engl Ed)"},{"key":"R17-20260519","doi-asserted-by":"crossref","first-page":"555","DOI":"10.23876\/j.krcp.21.900","article-title":"Angiotensin receptor-neprilysin inhibitor in patients with heart failure and chronic kidney disease.","volume":"40","author":"Cho","year":"2021","journal-title":"Kidney Res Clin Pract"},{"key":"R18-20260519","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1136\/bmjebm-2017-110853","article-title":"Methodological quality and synthesis of case series and case reports.","volume":"23","author":"Murad","year":"2018","journal-title":"BMJ Evid Based Med"},{"key":"R19-20260519","doi-asserted-by":"crossref","first-page":"794707","DOI":"10.3389\/fcvm.2022.794707","article-title":"Angiotensin receptor-neprilysin inhibitors in patients with heart failure with reduced ejection fraction and advanced chronic kidney disease: a retrospective multi-institutional study.","volume":"9","author":"Hsiao","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"R20-20260519","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1002\/ehf2.12659","article-title":"Sacubitril\/valsartan in patients with heart failure with reduced ejection fraction with end-stage of renal disease.","volume":"7","author":"Lee","year":"2020","journal-title":"ESC Heart Fail"},{"key":"R21-20260519","doi-asserted-by":"crossref","first-page":"657067","DOI":"10.3389\/fmed.2021.657067","article-title":"Effects of sacubitril-valsartan in heart failure with preserved ejection fraction in patients undergoing peritoneal dialysis.","volume":"8","author":"Fu","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"R22-20260519","doi-asserted-by":"crossref","first-page":"955780","DOI":"10.3389\/fcvm.2022.955780","article-title":"Effects of sacubitril\/valsartan in ESRD patients undergoing hemodialysis with HFpEF.","volume":"9","author":"Guo","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"R23-20260519","doi-asserted-by":"crossref","first-page":"831541","DOI":"10.3389\/fmed.2022.831541","article-title":"Sacubitril-valsartan increases ultrafiltration in patients undergoing peritoneal dialysis: a short-term retrospective self-controlled study.","volume":"9","author":"Zhang","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"R24-20260519","first-page":"288","article-title":"Use of angiotensin receptor neprilysin inhibitor in patients on maintenance hemodialysis with reduced cardiac ejection fraction, real-world experience from a single center.","volume":"15","author":"Lihua","year":"2021","journal-title":"Iran J Kidney Dis"},{"key":"R25-20260519","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/jch.14635","article-title":"Efficacy and safety of sacubitril\/valsartan after switching from azilsartan in hemodialysis patients with hypertension.","volume":"25","author":"Iwashima","year":"2023","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"R26-20260519","first-page":"3439","article-title":"Effects and safety of sacubitril\/valsartan (SV) on heart function and blood pressure in maintenance hemodialysis (MHD) patients.","volume":"14","author":"Wen","year":"2022","journal-title":"Am J Transl Res"},{"key":"R27-20260519","doi-asserted-by":"crossref","first-page":"i1219","DOI":"10.1093\/ndt\/gfad063d_6746","article-title":"Safety of angiotensin receptor-neprilisin inhibitor in peritoneal dialysis patients with heart failure: a multi-center cohort study.","volume":"38","author":"Pimenta","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"R28-20260519","doi-asserted-by":"crossref","first-page":"S161","DOI":"10.1016\/j.ekir.2023.02.364","article-title":"WCN23-1182 Safety and efficacy of sacubitril-valsartan in chronic kidney disease and dialysis patients with heart failure.","volume":"8","author":"Cairns","year":"2023","journal-title":"Kidney Int Rep"},{"key":"R29-20260519","doi-asserted-by":"crossref","DOI":"10.1093\/ndt\/gfad063b_5434","article-title":"#5434 Efficacy of sacubitril\/valsartan in maintenance hemodialysis patients with heart failure with preserved ejection fraction.","volume":"38","author":"Fu","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"R30-20260519","first-page":"1098","article-title":"Effectiveness of sacubitril-valsartan in the treatment of heart failure in ESKD patients on maintenance hemodialysis.","volume":"30","author":"Santhakumari","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"R31-20260519","doi-asserted-by":"crossref","first-page":"e026407","DOI":"10.1161\/JAHA.122.026407","article-title":"Sacubitril\/valsartan in patients with heart failure and concomitant end-stage kidney disease.","volume":"11","author":"Niu","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"R32-20260519","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1159\/000531217","article-title":"Study on the efficacy of sacubitril\/valsartan in patients with heart failure with preserved ejection fraction undergoing peritoneal dialysis.","volume":"148","author":"Sheng","year":"2023","journal-title":"Cardiology"},{"key":"R33-20260519","doi-asserted-by":"crossref","first-page":"1055330","DOI":"10.3389\/fmed.2022.1055330","article-title":"The efficacy and safety of sacubitril\/valsartan on pulmonary hypertension in hemodialysis patients.","volume":"9","author":"Zhao","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"R34-20260519","doi-asserted-by":"crossref","first-page":"2222841","DOI":"10.1080\/0886022X.2023.2222841","article-title":"Effects of sacubitril-valsartan in patients undergoing maintenance dialysis.","volume":"45","author":"Ding","year":"2023","journal-title":"Ren Fail"},{"key":"R35-20260519","first-page":"117","article-title":"Efficacy of sacubitril\/valsartan in peritoneal dialysis patients with HFpEF and its effect on residual renal function.","volume":"103","author":"Ma","year":"2023","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"R36-20260519","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1002\/clc.24075","article-title":"Effects of sacubitril-valsartan in the treatment of chronic heart failure patients with end-stage renal disease undergoing dialysis.","volume":"46","author":"Liu","year":"2023","journal-title":"Clin Cardiol"},{"key":"R37-20260519","doi-asserted-by":"crossref","first-page":"101149","DOI":"10.1016\/j.eclinm.2021.101149","article-title":"Clinical outcomes of sacubitril\/valsartan in patients with acute heart failure: a multi-institution study.","volume":"41","author":"Chen","year":"2021","journal-title":"EClinicalMedicine"},{"key":"R38-20260519","doi-asserted-by":"crossref","DOI":"10.1093\/ndt\/gfab097.007","article-title":"MO727 effect of sacubitril\/valsartan on serum potassium and blood pressure levels of dialysis patients with heart failure.","volume":"36","author":"Gula","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"R39-20260519","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.mayocp.2022.06.007","article-title":"Real-world experience of angiotensin receptor-neprilysin inhibition in reduced ejection fraction heart failure patients with advanced kidney disease.","volume":"98","author":"Chang","year":"2023","journal-title":"Mayo Clin Proc"},{"key":"R40-20260519","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1007\/s00228-016-2072-7","article-title":"Effect of renal function on the pharmacokinetics of LCZ696 (sacubitril\/valsartan), an angiotensin receptor neprilysin inhibitor.","volume":"72","author":"Ayalasomayajula","year":"2016","journal-title":"Eur J Clin Pharmacol"},{"key":"R41-20260519","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jchf.2018.02.004","article-title":"Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure.","volume":"6","author":"Damman","year":"2018","journal-title":"JACC Heart Fail"},{"key":"R42-20260519","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s11255-023-03599-w","article-title":"The efficacy and safety of sacubitril\/valsartan in chronic kidney disease: a systematic review and meta-analysis.","volume":"56","author":"Zhou","year":"2023","journal-title":"Int Urol Nephrol"},{"key":"R43-20260519","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1161\/CIRCULATIONAHA.118.034818","article-title":"Effects of sacubitril\/valsartan versus irbesartan in patients with chronic kidney disease.","volume":"138","author":"Haynes","year":"2018","journal-title":"Circulation"},{"key":"R44-20260519","first-page":"213","article-title":"Chronic kidney disease and end-stage renal disease-a review produced to contribute to the report \u2018the status of health in the European union: towards a healthier Europe\u2019.","volume":"3","author":"Zoccali","year":"2010","journal-title":"NDT Plus"},{"key":"R45-20260519","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1093\/ndt\/gfad038","article-title":"Pharmacokinetics and pharmacodynamics of sacubitril\/valsartan in peritoneal dialysis patients.","volume":"38","author":"He","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"R46-20260519","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1159\/000519643","article-title":"Pharmacokinetics and pharmacodynamics of sacubitril\/valsartan in maintenance hemodialysis patients with heart failure.","volume":"51","author":"Feng","year":"2022","journal-title":"Blood Purif"},{"key":"R47-20260519","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines.","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"R48-20260519","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s40520-021-01960-6","article-title":"Comparison of mortality prediction scores in elderly patients with ICD for heart failure with reduced ejection fraction.","volume":"34","author":"Hayiro\u011flu","year":"2022","journal-title":"Aging Clin Exp Res"},{"key":"R49-20260519","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/pace.14170","article-title":"Prognostic nutritional index as the predictor of long-term mortality among HFrEF patients with ICD.","volume":"44","author":"\u00c7inier","year":"2021","journal-title":"Pacing Clin Electrophysiol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000046866","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T13:02:39Z","timestamp":1779195759000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000046866"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,30]]},"references-count":49,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000046866","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,30]]},"assertion":[{"value":"2025-05-08","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-03","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}